Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Purchased by XTX Topco Ltd

Key Points

• XTX Topco Ltd increased its holdings in Amneal Pharmaceuticals by 110.7%, acquiring an additional 43,221 shares, bringing its total to 82,276 shares worth approximately $689,000.
• Several institutional investors, including Nantahala Capital Management and Bank of America, significantly boosted their stakes in Amneal Pharmaceuticals, indicating growing institutional interest in the company.
• Amneal Pharmaceuticals stock has a market cap of $2.49 billion and analysts project an earnings per share of 0.53 for the current fiscal year, with a consensus price target of $11.60.

XTX Topco Ltd grew its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 110.7% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 82,276 shares of the company's stock after buying an additional 43,221 shares during the period. XTX Topco Ltd's holdings in Amneal Pharmaceuticals were worth $689,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. KLP Kapitalforvaltning AS bought a new stake in Amneal Pharmaceuticals during the fourth quarter worth $219,000. Vanguard Group Inc. grew its position in Amneal Pharmaceuticals by 1.5% during the fourth quarter. Vanguard Group Inc. now owns 14,841,969 shares of the company's stock worth $117,548,000 after buying an additional 218,025 shares in the last quarter. Alliancebernstein L.P. increased its position in shares of Amneal Pharmaceuticals by 2.5% during the 4th quarter. Alliancebernstein L.P. now owns 200,246 shares of the company's stock valued at $1,586,000 after purchasing an additional 4,927 shares during the last quarter. Geode Capital Management LLC lifted its position in Amneal Pharmaceuticals by 0.7% in the 4th quarter. Geode Capital Management LLC now owns 3,813,207 shares of the company's stock worth $30,207,000 after buying an additional 26,536 shares during the last quarter. Finally, Trexquant Investment LP lifted its stake in shares of Amneal Pharmaceuticals by 93.2% in the 4th quarter. Trexquant Investment LP now owns 462,720 shares of the company's stock valued at $3,665,000 after acquiring an additional 223,158 shares during the last quarter. Institutional investors and hedge funds own 31.82% of the company's stock.

Amneal Pharmaceuticals Trading Up 3.5%

Shares of AMRX stock traded up $0.29 during trading hours on Friday, reaching $8.50. 1,239,769 shares of the company's stock were exchanged, compared to its average volume of 1,672,656. The stock's 50 day moving average is $7.99 and its 200-day moving average is $7.96. The company has a market cap of $2.66 billion, a price-to-earnings ratio of 850.35 and a beta of 1.11. Amneal Pharmaceuticals, Inc. has a fifty-two week low of $6.68 and a fifty-two week high of $9.48.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $0.23 EPS for the quarter, beating the consensus estimate of $0.17 by $0.06. Amneal Pharmaceuticals had a net margin of 0.12% and a negative return on equity of 189.49%. Equities analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have commented on AMRX shares. The Goldman Sachs Group started coverage on Amneal Pharmaceuticals in a research report on Friday, June 6th. They set a "buy" rating and a $12.00 price target for the company. Wall Street Zen cut Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, May 13th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, Amneal Pharmaceuticals presently has a consensus rating of "Buy" and a consensus target price of $11.60.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.